Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new consortium of 27 partners coordinated by the Nuffield Department of Clinical Neurosciences will tackle the challenge of discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative and metabolic diseases.

With this funding, we will be able to develop more sophisticated models that replicate the human blood-brain barrier far more accurately, allowing us to investigate how the barrier acts at a molecular level during disease.
- Zam Cader

The blood-brain barrier is a protective layer between the brain’s blood capillaries and the cells that make up brain tissue. This barrier provides a defence against the pathogens and toxins that may be in our blood, allowing very few molecules to pass through. It can also prevent many drugs from passing across into the brain, and this presents a major problem in treating neurological conditions and metabolic diseases, especially when using antibody therapies. On the other hand, several neurological diseases could originate from a dysfunctional blood-brain barrier.

The funding from the Innovative Medicines Initiative (IMI) to the IM2PACT consortium will allow this public-private partnership, which includes leading international experts in the field, to facilitate the development of drugs to treat neurological disorders by: 

  • discovering and developing innovative and effective brain transport mechanisms
  • establishing and characterising blood-brain barrier models with good predictability in health and disease
  • identifying translational read-outs closer to the pathogenesis of neurodegeneration and mimicking altered blood-brain barrier under disease conditions
  • in-depth understanding of the biology of the blood-brain barrier and characterisation of various pathophysiological mechanisms across the blood-brain barrier.

IM2PACT will foster the development of disease-modifying treatment in a setting of personalised medicine.

Dominique Lesuisse, Head of the Central Nervous System Barrier Group at Sanofi and IM2PACT project leader, said: 'Our existing models are not effective enough at telling us which drugs in particular biotherapeutics will break through the blood-brain barrier. IM2PACT will progress the state of the art and help devise optimal ways of getting therapies into the brain.'

With a budget of €18m, €9m of direct funding from IMI and €9m of in-kind funding from industry, IM2PACT is forming a large partnership to better understand the blood-brain barrier. The Innovative Medicines Initiative 2 Joint Undertaking is Europe’s biggest public private partnership and is funded jointly by the European Union´s Horizon 2020 research and innovation programme and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). 

 

Similar stories

Collaborating with Youth is Key to Studying Mental Health Management

Research Highlights

The Global Mental Health Databank, a feasibility study, hopes to enable youth from the United Kingdom, South Africa, and India to work directly with mental health researchers to better understand how young people can manage their own mental health.

SSRI Treatment in Young People with Depression and Anxiety

Research Highlights

Results from an insight review commissioned by the Wellcome Trust, highlights what is currently known about the benefits and risks of using selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression and anxiety in young people.

The brain understands relationships in the same way as it understands how to move in space

Research Highlights

Researchers led by a team at the Wellcome Centre for Integrative Neuroimaging at the University of Oxford have developed a new framework that binds together the way the brain forms maps of space to the way the brain understands relationships of any kind – general mental maps.

Researchers reveal surprising simplicity behind our ability to hear

Research Highlights

A computational modelling study from the King Group demonstrates that the way sounds are transformed from the ear to the brain’s auditory cortex may be simpler than expected. These findings not only highlight the value of computational modelling for determining the principles underlying neural processing, but could also be useful for improving treatments for patients with hearing loss.